Compile Data Set for Download or QSAR

Found 46 hits with Last Name = 'hernandez' and Initial = 'pe'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050933 ((S)-2-((S)-2-{(S)-2-[3-(4-Chloro-phenyl)-ureido]-4...) Show SMILES CSCC[C@H](NC(=O)Nc1ccc(Cl)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C27H35ClN4O5S/c1-17(2)15-22(25(34)31-23(26(35)36)16-18-7-5-4-6-8-18)30-24(33)21(13-14-38-3)32-27(37)29-20-11-9-19(28)10-12-20/h4-12,17,21-23H,13-16H2,1-3H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t21-,22-,23-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050929 (2-((S)-2-{(S)-2-[3-(4-Methoxy-phenyl)-ureido]-4-me...) Show SMILES COc1ccc(NC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)NC(Cc2ccccc2)C(O)=O)cc1 Show InChI InChI=1S/C28H38N4O6S/c1-18(2)16-23(26(34)31-24(27(35)36)17-19-8-6-5-7-9-19)30-25(33)22(14-15-39-4)32-28(37)29-20-10-12-21(38-3)13-11-20/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24?/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050935 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CSCC[C@H](NC(=O)Nc1ccc(C)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-18(2)16-23(26(34)31-24(27(35)36)17-20-8-6-5-7-9-20)30-25(33)22(14-15-38-4)32-28(37)29-21-12-10-19(3)11-13-21/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050945 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Adamantan-1-y...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:42:43:47:41.40.46,46:41:48:45.47.44,46:45:48:41.40.42,THB:42:41:47:43.48.44| Show InChI InChI=1S/C50H66N6O7/c1-31(2)20-39(52-47(60)42(26-34-16-10-6-11-17-34)55-49(63)56-50-28-36-22-37(29-50)24-38(23-36)30-50)44(57)53-41(25-33-14-8-5-9-15-33)46(59)51-40(21-32(3)4)45(58)54-43(48(61)62)27-35-18-12-7-13-19-35/h5-19,31-32,36-43H,20-30H2,1-4H3,(H,51,59)(H,52,60)(H,53,57)(H,54,58)(H,61,62)(H2,55,56,63)/t36?,37?,38?,39-,40-,41+,42+,43+,50?/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	20	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050928 ((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C47H58N6O7/c1-30(2)24-37(50-45(57)40(28-34-19-11-7-12-20-34)53-47(60)48-36-23-15-16-32(5)26-36)42(54)51-39(27-33-17-9-6-10-18-33)44(56)49-38(25-31(3)4)43(55)52-41(46(58)59)29-35-21-13-8-14-22-35/h6-23,26,30-31,37-41H,24-25,27-29H2,1-5H3,(H,49,56)(H,50,57)(H,51,54)(H,52,55)(H,58,59)(H2,48,53,60)/t37-,38-,39+,40+,41+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	20	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050937 ((S)-2-[(S)-2-((S)-2-Formylamino-4-methylsulfanyl-b...) Show SMILES CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE KEGG MMDB PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	20	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050946 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CSCC[C@H](NC(=O)Nc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C27H36N4O5S/c1-18(2)16-22(25(33)30-23(26(34)35)17-19-10-6-4-7-11-19)29-24(32)21(14-15-37-3)31-27(36)28-20-12-8-5-9-13-20/h4-13,18,21-23H,14-17H2,1-3H3,(H,29,32)(H,30,33)(H,34,35)(H2,28,31,36)/t21-,22-,23-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	30	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050942 ((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C46H56N6O7/c1-30(2)25-36(49-44(56)39(28-33-19-11-6-12-20-33)52-46(59)47-35-23-15-8-16-24-35)41(53)50-38(27-32-17-9-5-10-18-32)43(55)48-37(26-31(3)4)42(54)51-40(45(57)58)29-34-21-13-7-14-22-34/h5-24,30-31,36-40H,25-29H2,1-4H3,(H,48,55)(H,49,56)(H,50,53)(H,51,54)(H,57,58)(H2,47,52,59)/t36-,37-,38+,39+,40+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	50	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050939 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...) Show SMILES CSCC[C@H](NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-18(2)15-23(26(34)31-24(27(35)36)17-20-10-6-5-7-11-20)30-25(33)22(13-14-38-4)32-28(37)29-21-12-8-9-19(3)16-21/h5-12,16,18,22-24H,13-15,17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	100	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050926 ((S)-2-((R)-4-Methyl-2-{(S)-2-[(R)-4-methyl-2-((S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C40H52N6O7/c1-25(2)20-30(43-38(50)33(46-40(41)53)23-28-16-10-6-11-17-28)35(47)44-32(22-27-14-8-5-9-15-27)37(49)42-31(21-26(3)4)36(48)45-34(39(51)52)24-29-18-12-7-13-19-29/h5-19,25-26,30-34H,20-24H2,1-4H3,(H,42,49)(H,43,50)(H,44,47)(H,45,48)(H,51,52)(H3,41,46,53)/t30-,31-,32+,33+,34+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	100	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050928 ((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C47H58N6O7/c1-30(2)24-37(50-45(57)40(28-34-19-11-7-12-20-34)53-47(60)48-36-23-15-16-32(5)26-36)42(54)51-39(27-33-17-9-6-10-18-33)44(56)49-38(25-31(3)4)43(55)52-41(46(58)59)29-35-21-13-8-14-22-35/h6-23,26,30-31,37-41H,24-25,27-29H2,1-5H3,(H,49,56)(H,50,57)(H,51,54)(H,52,55)(H,58,59)(H2,48,53,60)/t37-,38-,39+,40+,41+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	200	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050943 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Isopropyl-ure...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C43H58N6O7/c1-27(2)22-33(46-41(53)36(49-43(56)44-29(5)6)25-31-18-12-8-13-19-31)38(50)47-35(24-30-16-10-7-11-17-30)40(52)45-34(23-28(3)4)39(51)48-37(42(54)55)26-32-20-14-9-15-21-32/h7-21,27-29,33-37H,22-26H2,1-6H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,54,55)(H2,44,49,56)/t33-,34-,35+,36+,37+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	200	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050931 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Butyl-ureido)...) Show SMILES CCCCNC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C44H60N6O7/c1-6-7-23-45-44(57)50-37(27-32-19-13-9-14-20-32)42(54)47-34(24-29(2)3)39(51)48-36(26-31-17-11-8-12-18-31)41(53)46-35(25-30(4)5)40(52)49-38(43(55)56)28-33-21-15-10-16-22-33/h8-22,29-30,34-38H,6-7,23-28H2,1-5H3,(H,46,53)(H,47,54)(H,48,51)(H,49,52)(H,55,56)(H2,45,50,57)/t34-,35-,36+,37+,38+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	300	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050927 ((S)-2-{(S)-2-[(S)-2-(3-Isopropenyl-ureido)-4-methy...) Show SMILES [#6]-[#16]-[#6]-[#6]-[#6@H](-[#7]-[#6](=O)\[#7]=[#6](\[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccccc1)-[#6](-[#8])=O Show InChI InChI=1S/C24H36N4O5S/c1-15(2)13-19(22(30)27-20(23(31)32)14-17-9-7-6-8-10-17)26-21(29)18(11-12-34-5)28-24(33)25-16(3)4/h6-10,15,18-20H,11-14H2,1-5H3,(H,26,29)(H,27,30)(H,28,33)(H,31,32)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	300	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050934 ((S)-2-{(S)-2-[(S)-2-(3-Butyl-ureido)-4-methylsulfa...) Show SMILES CCCCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-5-6-13-26-25(34)29-19(12-14-35-4)22(30)27-20(15-17(2)3)23(31)28-21(24(32)33)16-18-10-8-7-9-11-18/h7-11,17,19-21H,5-6,12-16H2,1-4H3,(H,27,30)(H,28,31)(H,32,33)(H2,26,29,34)/t19-,20-,21-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	300	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050945 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Adamantan-1-y...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:42:43:47:41.40.46,46:41:48:45.47.44,46:45:48:41.40.42,THB:42:41:47:43.48.44| Show InChI InChI=1S/C50H66N6O7/c1-31(2)20-39(52-47(60)42(26-34-16-10-6-11-17-34)55-49(63)56-50-28-36-22-37(29-50)24-38(23-36)30-50)44(57)53-41(25-33-14-8-5-9-15-33)46(59)51-40(21-32(3)4)45(58)54-43(48(61)62)27-35-18-12-7-13-19-35/h5-19,31-32,36-43H,20-30H2,1-4H3,(H,51,59)(H,52,60)(H,53,57)(H,54,58)(H,61,62)(H2,55,56,63)/t36?,37?,38?,39-,40-,41+,42+,43+,50?/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	300	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050942 ((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C46H56N6O7/c1-30(2)25-36(49-44(56)39(28-33-19-11-6-12-20-33)52-46(59)47-35-23-15-8-16-24-35)41(53)50-38(27-32-17-9-5-10-18-32)43(55)48-37(26-31(3)4)42(54)51-40(45(57)58)29-34-21-13-7-14-22-34/h5-24,30-31,36-40H,25-29H2,1-4H3,(H,48,55)(H,49,56)(H,50,53)(H,51,54)(H,57,58)(H2,47,52,59)/t36-,37-,38+,39+,40+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	500	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050943 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Isopropyl-ure...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C43H58N6O7/c1-27(2)22-33(46-41(53)36(49-43(56)44-29(5)6)25-31-18-12-8-13-19-31)38(50)47-35(24-30-16-10-7-11-17-30)40(52)45-34(23-28(3)4)39(51)48-37(42(54)55)26-32-20-14-9-15-21-32/h7-21,27-29,33-37H,22-26H2,1-6H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,54,55)(H2,44,49,56)/t33-,34-,35+,36+,37+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	500	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050931 ((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Butyl-ureido)...) Show SMILES CCCCNC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C44H60N6O7/c1-6-7-23-45-44(57)50-37(27-32-19-13-9-14-20-32)42(54)47-34(24-29(2)3)39(51)48-36(26-31-17-11-8-12-18-31)41(53)46-35(25-30(4)5)40(52)49-38(43(55)56)28-33-21-15-10-16-22-33/h8-22,29-30,34-38H,6-7,23-28H2,1-5H3,(H,46,53)(H,47,54)(H,48,51)(H,49,52)(H,55,56)(H2,45,50,57)/t34-,35-,36+,37+,38+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	600	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050940 ((S)-2-{(S)-2-[(S)-2-(3-Benzyl-ureido)-4-methylsulf...) Show SMILES CSCC[C@H](NC(=O)NCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-19(2)16-23(26(34)31-24(27(35)36)17-20-10-6-4-7-11-20)30-25(33)22(14-15-38-3)32-28(37)29-18-21-12-8-5-9-13-21/h4-13,19,22-24H,14-18H2,1-3H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	600	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050940 ((S)-2-{(S)-2-[(S)-2-(3-Benzyl-ureido)-4-methylsulf...) Show SMILES CSCC[C@H](NC(=O)NCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-19(2)16-23(26(34)31-24(27(35)36)17-20-10-6-4-7-11-20)30-25(33)22(14-15-38-3)32-28(37)29-18-21-12-8-5-9-13-21/h4-13,19,22-24H,14-18H2,1-3H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	800	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050926 ((S)-2-((R)-4-Methyl-2-{(S)-2-[(R)-4-methyl-2-((S)-...) Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C40H52N6O7/c1-25(2)20-30(43-38(50)33(46-40(41)53)23-28-16-10-6-11-17-28)35(47)44-32(22-27-14-8-5-9-15-27)37(49)42-31(21-26(3)4)36(48)45-34(39(51)52)24-29-18-12-7-13-19-29/h5-19,25-26,30-34H,20-24H2,1-4H3,(H,42,49)(H,43,50)(H,44,47)(H,45,48)(H,51,52)(H3,41,46,53)/t30-,31-,32+,33+,34+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	800	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050944 ((S)-2-{(S)-2-[(S)-2-(3-Adamantan-1-yl-ureido)-4-me...) Show SMILES CSCC[C@H](NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:12:13:17:11.10.16,THB:12:11:17:13.18.14,14:13:10:15.17.16,14:15:10:13.18.12| Show InChI InChI=1S/C31H46N4O5S/c1-19(2)11-25(28(37)33-26(29(38)39)15-20-7-5-4-6-8-20)32-27(36)24(9-10-41-3)34-30(40)35-31-16-21-12-22(17-31)14-23(13-21)18-31/h4-8,19,21-26H,9-18H2,1-3H3,(H,32,36)(H,33,37)(H,38,39)(H2,34,35,40)/t21?,22?,23?,24-,25-,26-,31?/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	900	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050948 ((S)-2-{(S)-2-[(S)-2-(3-Ethyl-ureido)-4-methylsulfa...) Show SMILES CCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C23H36N4O5S/c1-5-24-23(32)27-17(11-12-33-4)20(28)25-18(13-15(2)3)21(29)26-19(22(30)31)14-16-9-7-6-8-10-16/h6-10,15,17-19H,5,11-14H2,1-4H3,(H,25,28)(H,26,29)(H,30,31)(H2,24,27,32)/t17-,18-,19-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050938 ((S)-2-{(S)-2-[(S)-2-(3-Isobutyl-ureido)-4-methylsu...) Show SMILES CSCC[C@H](NC(=O)NCC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-16(2)13-20(23(31)28-21(24(32)33)14-18-9-7-6-8-10-18)27-22(30)19(11-12-35-5)29-25(34)26-15-17(3)4/h6-10,16-17,19-21H,11-15H2,1-5H3,(H,27,30)(H,28,31)(H,32,33)(H2,26,29,34)/t19-,20-,21-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050939 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...) Show SMILES CSCC[C@H](NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-18(2)15-23(26(34)31-24(27(35)36)17-20-10-6-5-7-11-20)30-25(33)22(13-14-38-4)32-28(37)29-21-12-8-9-19(3)16-21/h5-12,16,18,22-24H,13-15,17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	1.60E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050941 ((S)-2-[(S)-4-Methyl-2-((S)-4-methylsulfanyl-2-urei...) Show SMILES CSCC[C@H](NC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C21H32N4O5S/c1-13(2)11-16(23-18(26)15(9-10-31-3)25-21(22)30)19(27)24-17(20(28)29)12-14-7-5-4-6-8-14/h4-8,13,15-17H,9-12H2,1-3H3,(H,23,26)(H,24,27)(H,28,29)(H3,22,25,30)/t15-,16-,17-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050930 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...) Show SMILES CNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C22H34N4O5S/c1-14(2)12-17(24-19(27)16(10-11-32-4)26-22(31)23-3)20(28)25-18(21(29)30)13-15-8-6-5-7-9-15/h5-9,14,16-18H,10-13H2,1-4H3,(H,24,27)(H,25,28)(H,29,30)(H2,23,26,31)/t16-,17-,18-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050947 ((S)-2-{(S)-2-[(S)-2-(3-Isopropyl-ureido)-4-methyls...) Show SMILES CSCC[C@H](NC(=O)NC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C24H38N4O5S/c1-15(2)13-19(22(30)27-20(23(31)32)14-17-9-7-6-8-10-17)26-21(29)18(11-12-34-5)28-24(33)25-16(3)4/h6-10,15-16,18-20H,11-14H2,1-5H3,(H,26,29)(H,27,30)(H,31,32)(H2,25,28,33)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050936 ((S)-2-{(S)-2-[(S)-2-(3-tert-Butyl-ureido)-4-methyl...) Show SMILES CSCC[C@H](NC(=O)NC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-16(2)14-19(22(31)27-20(23(32)33)15-17-10-8-7-9-11-17)26-21(30)18(12-13-35-6)28-24(34)29-25(3,4)5/h7-11,16,18-20H,12-15H2,1-6H3,(H,26,30)(H,27,31)(H,32,33)(H2,28,29,34)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050944 ((S)-2-{(S)-2-[(S)-2-(3-Adamantan-1-yl-ureido)-4-me...) Show SMILES CSCC[C@H](NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:12:13:17:11.10.16,THB:12:11:17:13.18.14,14:13:10:15.17.16,14:15:10:13.18.12| Show InChI InChI=1S/C31H46N4O5S/c1-19(2)11-25(28(37)33-26(29(38)39)15-20-7-5-4-6-8-20)32-27(36)24(9-10-41-3)34-30(40)35-31-16-21-12-22(17-31)14-23(13-21)18-31/h4-8,19,21-26H,9-18H2,1-3H3,(H,32,36)(H,33,37)(H,38,39)(H2,34,35,40)/t21?,22?,23?,24-,25-,26-,31?/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050932 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CCCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C24H38N4O5S/c1-5-12-25-24(33)28-18(11-13-34-4)21(29)26-19(14-16(2)3)22(30)27-20(23(31)32)15-17-9-7-6-8-10-17/h6-10,16,18-20H,5,11-15H2,1-4H3,(H,26,29)(H,27,30)(H,31,32)(H2,25,28,33)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	2.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050932 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CCCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C24H38N4O5S/c1-5-12-25-24(33)28-18(11-13-34-4)21(29)26-19(14-16(2)3)22(30)27-20(23(31)32)15-17-9-7-6-8-10-17/h6-10,16,18-20H,5,11-15H2,1-4H3,(H,26,29)(H,27,30)(H,31,32)(H2,25,28,33)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	3.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050948 ((S)-2-{(S)-2-[(S)-2-(3-Ethyl-ureido)-4-methylsulfa...) Show SMILES CCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C23H36N4O5S/c1-5-24-23(32)27-17(11-12-33-4)20(28)25-18(13-15(2)3)21(29)26-19(22(30)31)14-16-9-7-6-8-10-16/h6-10,15,17-19H,5,11-14H2,1-4H3,(H,25,28)(H,26,29)(H,30,31)(H2,24,27,32)/t17-,18-,19-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	3.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050936 ((S)-2-{(S)-2-[(S)-2-(3-tert-Butyl-ureido)-4-methyl...) Show SMILES CSCC[C@H](NC(=O)NC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-16(2)14-19(22(31)27-20(23(32)33)15-17-10-8-7-9-11-17)26-21(30)18(12-13-35-6)28-24(34)29-25(3,4)5/h7-11,16,18-20H,12-15H2,1-6H3,(H,26,30)(H,27,31)(H,32,33)(H2,28,29,34)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	3.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050930 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...) Show SMILES CNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C22H34N4O5S/c1-14(2)12-17(24-19(27)16(10-11-32-4)26-22(31)23-3)20(28)25-18(21(29)30)13-15-8-6-5-7-9-15/h5-9,14,16-18H,10-13H2,1-4H3,(H,24,27)(H,25,28)(H,29,30)(H2,23,26,31)/t16-,17-,18-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	3.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Binding affinity towards fMLF receptor using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050938 ((S)-2-{(S)-2-[(S)-2-(3-Isobutyl-ureido)-4-methylsu...) Show SMILES CSCC[C@H](NC(=O)NCC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-16(2)13-20(23(31)28-21(24(32)33)14-18-9-7-6-8-10-18)27-22(30)19(11-12-35-5)29-25(34)26-15-17(3)4/h6-10,16-17,19-21H,11-15H2,1-5H3,(H,27,30)(H,28,31)(H,32,33)(H2,26,29,34)/t19-,20-,21-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	4.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050947 ((S)-2-{(S)-2-[(S)-2-(3-Isopropyl-ureido)-4-methyls...) Show SMILES CSCC[C@H](NC(=O)NC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C24H38N4O5S/c1-15(2)13-19(22(30)27-20(23(31)32)14-17-9-7-6-8-10-17)26-21(29)18(11-12-34-5)28-24(33)25-16(3)4/h6-10,15-16,18-20H,11-14H2,1-5H3,(H,26,29)(H,27,30)(H,31,32)(H2,25,28,33)/t18-,19-,20-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	5.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050946 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CSCC[C@H](NC(=O)Nc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C27H36N4O5S/c1-18(2)16-22(25(33)30-23(26(34)35)17-19-10-6-4-7-11-19)29-24(32)21(14-15-37-3)31-27(36)28-20-12-8-5-9-13-20/h4-13,18,21-23H,14-17H2,1-3H3,(H,29,32)(H,30,33)(H,34,35)(H2,28,31,36)/t21-,22-,23-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	40	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050935 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...) Show SMILES CSCC[C@H](NC(=O)Nc1ccc(C)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-18(2)16-23(26(34)31-24(27(35)36)17-20-8-6-5-7-9-20)30-25(33)22(14-15-38-4)32-28(37)29-21-12-10-19(3)11-13-21/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	2	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050939 ((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...) Show SMILES CSCC[C@H](NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C28H38N4O5S/c1-18(2)15-23(26(34)31-24(27(35)36)17-20-10-6-5-7-11-20)30-25(33)22(13-14-38-4)32-28(37)29-21-12-8-9-19(3)16-21/h5-12,16,18,22-24H,13-15,17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	900	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050934 ((S)-2-{(S)-2-[(S)-2-(3-Butyl-ureido)-4-methylsulfa...) Show SMILES CCCCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C25H40N4O5S/c1-5-6-13-26-25(34)29-19(12-14-35-4)22(30)27-20(15-17(2)3)23(31)28-21(24(32)33)16-18-10-8-7-9-11-18/h7-11,17,19-21H,5-6,12-16H2,1-4H3,(H,27,30)(H,28,31)(H,32,33)(H2,26,29,34)/t19-,20-,21-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	300	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050933 ((S)-2-((S)-2-{(S)-2-[3-(4-Chloro-phenyl)-ureido]-4...) Show SMILES CSCC[C@H](NC(=O)Nc1ccc(Cl)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C27H35ClN4O5S/c1-17(2)15-22(25(34)31-23(26(35)36)16-18-7-5-4-6-8-18)30-24(33)21(13-14-38-3)32-27(37)29-20-11-9-19(28)10-12-20/h4-12,17,21-23H,13-16H2,1-3H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t21-,22-,23-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	1	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050937 ((S)-2-[(S)-2-((S)-2-Formylamino-4-methylsulfanyl-b...) Show SMILES CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE KEGG MMDB PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	n/a	n/a	20	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050929 (2-((S)-2-{(S)-2-[3-(4-Methoxy-phenyl)-ureido]-4-me...) Show SMILES COc1ccc(NC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)NC(Cc2ccccc2)C(O)=O)cc1 Show InChI InChI=1S/C28H38N4O6S/c1-18(2)16-23(26(34)31-24(27(35)36)17-19-8-6-5-7-9-19)30-25(33)22(14-15-39-4)32-28(37)29-20-10-12-21(38-3)13-11-20/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24?/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	1	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair
fMet-Leu-Phe receptor (Homo sapiens (Human))	BDBM50050941 ((S)-2-[(S)-4-Methyl-2-((S)-4-methylsulfanyl-2-urei...) Show SMILES CSCC[C@H](NC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O Show InChI InChI=1S/C21H32N4O5S/c1-13(2)11-16(23-18(26)15(9-10-31-3)25-21(22)30)19(27)24-17(20(28)29)12-14-7-5-4-6-8-14/h4-8,13,15-17H,9-12H2,1-3H3,(H,23,26)(H,24,27)(H,28,29)(H3,22,25,30)/t15-,16-,17-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	n/a	n/a	3.00E+3	n/a	n/a	n/a	n/a
Johnson Matthey Biomedical Research Curated by ChEMBL					Assay Description Agonistic activity was determined by measuring the ability to induce superoxide production(as measured by reduction of cytochrome C) using human neut...				J Med Chem 39: 1013-5 (1996) Article DOI: 10.1021/jm950908d BindingDB Entry DOI: 10.7270/Q2TD9WF6
					More data for this Ligand-Target Pair